A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000001382
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
Not provided
Exclusion Criteria
1)The subject has taken other diabetic medications than pioglitazone within 16 weeks before the initiation of the treatment period (Week 0) 2)The subject with a history or symptoms of cardiac failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c change at the completion of treatment from baseline
- Secondary Outcome Measures
Name Time Method